Revolution Medicines, Inc. (RVMD) Stock Analysis and Metrics

Revolution Medicines

NASDAQ: RVMD

$189.17 ▲ +0.42 (+0.22%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap37.37 Bn

P/E-27.24

Div. Yield0.00

Add ratio to table…

About

Revolution Medicines, Inc. was founded in October 2014 as a Delaware corporation. The company is a clinical stage precision oncology enterprise dedicated to discovering and developing novel targeted therapies for cancers driven by RAS mutations. Its scientific approach centers on a proprietary tri complex technology platform that enables the design of small molecules capable of binding to unconventional sites on the active GTP bound form of RAS known as RAS(ON). The company’s pipeline includes a portfolio of RAS(ON) inhibitors that are either multi selective across several RAS mutants or mutant selective for individual alleles such as KRAS G12C KRAS G12D KRAS G12V and KRAS Q61H. These agents are being evaluated in clinical trials for indications including pancreatic ductal adenocarcinoma non small cell lung cancer and colorectal cancer. The ultimate goal of Revolution Medicines is to deliver innovative medicines that improve outcomes for patients with RAS addicted cancers.

Revolution Medicines does not currently market any approved products and therefore its revenue is derived mainly from collaborative agreements with pharmaceutical partners. The company has entered into multiple clinical collaborations that provide upfront cash payments research funding and milestone reimbursements tied to preclinical and clinical development achievements. Notable collaborations include a partnership with Bristol Myers Squibb to evaluate daraxonrasib in combination with navlimetostat in pancreatic ductal adenocarcinoma patients. Another collaboration with Amgen focuses on the combination of daraxonrasib with AMG 193 in previously treated metastatic pancreatic ductal adenocarcinoma. The company also works with Summit Therapeutics to assess daraxonrasib elironrasib and zoldonrasib in combination with ivonescimab across various solid tumor settings. Additional partnerships involve Iambic Therapeutics for artificial intelligence aided lead discovery Tango Therapeutics for PRMT5 inhibitor combinations Break Through Cancer for biomarker research and Aethon Therapeutics for bispecific antibody studies. These agreements may generate future royalty streams if any of the partnered product candidates receive regulatory approval and achieve commercial sales. Revolution Medicines also pursues government grants and nonprofit funding to support its research programs although such sources represent a smaller portion of total revenue.

Revolution Medicines occupies a niche within the broader oncology market by targeting the RAS(ON) conformation which has historically been considered difficult to drug. Most approved RAS inhibitors such as sotorasib and adagrasib bind to the inactive RAS(OFF) state and therefore face rapid resistance through pathway reactivation. In contrast the company’s tri complex inhibitors directly engage RAS(ON) aiming to achieve deeper and more durable suppression of oncogenic signaling. This mechanistic distinction provides a potential advantage over existing KRAS G12C directed therapies and positions the firm to address a wider spectrum of RAS mutant tumors including those with KRAS G12D KRAS G12V KRAS Q61 and NRAS or HRAS alterations. The competitive landscape features numerous large pharmaceutical companies biotech firms and academic groups pursuing KRAS G12C inhibitors as well as programs exploring pan RAS or pan KRAS strategies. Key competitors referenced in public disclosures include Amgen Betta Pharmaceuticals Bristol Myers Squibb Eli Lilly Roche Genentech and various academic consortia. Revolution Medicines differentiates itself through its proprietary discovery platform its extensive chemical biology and cancer pharmacology know how and its ability to generate both multi selective and mutant selective compounds that can be combined to counteract resistance mechanisms. The firm’s intellectual property portfolio which includes patents covering its tri complex technology and specific inhibitor chemistries further supports its market position.

The company’s primary customers are patients diagnosed with RAS addicted cancers who participate in its clinical trials or who will receive its therapies upon regulatory approval. In the development phase Revolution Medicines collaborates with pharmaceutical partners that serve as co sponsors and customers for its investigative agents. These partners include Bristol Myers Squibb Amgen Summit Therapeutics Iambic Therapeutics Tango Therapeutics Break Through Cancer and Aethon Therapeutics which provide clinical trial sites patient enrollment support and financial contributions. Beyond individual patients the firm anticipates serving hospitals oncology treatment centers academic medical centers and health systems that prescribe cancer therapies and manage infusion or oral drug administration. Additionally payers such as private insurers government healthcare programs and managed care organizations will become important customers once the company secures coverage and reimbursement approvals for its products. The firm’s commercialization strategy envisions a direct sales force in the United States supplemented by regional distributors in Europe and Asia to reach these customer groups.

Investment Thesis

▲ Bull case

Revolution Medicines is poised to capture significant market share in the pancreatic cancer space as diraxonrasib demonstrates transformative efficacy in previously treated metastatic disease, with a 60% reduction in death risk and median overall survival exceeding one year in RESOLUTE-302, positioning it as a potential new standard of care; this is reinforced by strong early access program demand and physician interest, as seen in the rapid patient inquiries at major cancer centers, indicating unmet need is being actively addressed and creating a pull-through effect that could accelerate adoption post-approval, particularly given the drug’s oral once-daily dosing and manageable safety profile compared to intensive chemotherapy regimens.
The company’s pipeline depth offers multiple near-term catalysts beyond diraxonrasib, including the ongoing RESOLUTE-303 trial evaluating diraxonrasib in first-line pancreatic cancer both as monotherapy and in combination with chemotherapy, which has shown promising six-month Kaplan-Meier estimates of 84% for PFS and 90% for OS in the combination arm, suggesting potential to delay or avoid chemotherapy altogether and expand the addressable patient population earlier in the disease trajectory, while parallel progress in zoldonrasib for G12D-mutant NSCLC—demonstrating a 52% ORR and 93% DCR in pre-treated patients—supports expansion into lung cancer, a larger indication with significant RAS mutation prevalence.
Strategic advancements in next-generation RAS(ON) inhibitors, particularly the catalytic inhibitor RM055, present a hidden catalyst not fully emphasized in management commentary; preclinical data show RM055 overcomes prior resistance mechanisms including RAS amplification and pathway reactivation, with deep and durable tumor regression in xenograft models that had escaped prior RAS inhibitor therapy, positioning it as a potential solution to acquired resistance and enabling lifecycle extension of the franchise, with a first-in-human trial planned for Q4 FY26, which could generate early clinical proof-of-concept before many investors anticipate.
Despite elevated GAAP operating expenses due to nonrecurring stock-based compensation adjustments, Revolution Medicines ended Q1 FY26 with $1.9 billion in cash and investments, strengthened to $2.1 billion post-quarter from the April dual-tranche capital raise, providing a multi-year runway to execute its aggressive clinical and commercialization plans without near-term financing pressure, allowing sustained investment in global launch readiness—including recent appointments of regional GMs for APAC, Japan, and Germany—and reducing reliance on dilution or partnerships to fund pivotal trials and pre-launch activities.

Revolution Medicines is poised to capture significant market share in the pancreatic cancer space as diraxonrasib demonstrates transformative efficacy in previously treated metastatic disease, with a 60% reduction in death risk and median overall survival exceeding one year in RESOLUTE-302, positioning it as a potential new standard of care; this is reinforced by strong early access program demand and physician interest, as seen in the rapid patient inquiries at major cancer centers, indicating unmet need is being actively addressed and creating a pull-through effect that could accelerate adoption post-approval, particularly given the drug’s oral once-daily dosing and manageable safety profile compared to intensive chemotherapy regimens.
The company’s pipeline depth offers multiple near-term catalysts beyond diraxonrasib, including the ongoing RESOLUTE-303 trial evaluating diraxonrasib in first-line pancreatic cancer both as monotherapy and in combination with chemotherapy, which has shown promising six-month Kaplan-Meier estimates of 84% for PFS and 90% for OS in the combination arm, suggesting potential to delay or avoid chemotherapy altogether and expand the addressable patient population earlier in the disease trajectory, while parallel progress in zoldonrasib for G12D-mutant NSCLC—demonstrating a 52% ORR and 93% DCR in pre-treated patients—supports expansion into lung cancer, a larger indication with significant RAS mutation prevalence.
Strategic advancements in next-generation RAS(ON) inhibitors, particularly the catalytic inhibitor RM055, present a hidden catalyst not fully emphasized in management commentary; preclinical data show RM055 overcomes prior resistance mechanisms including RAS amplification and pathway reactivation, with deep and durable tumor regression in xenograft models that had escaped prior RAS inhibitor therapy, positioning it as a potential solution to acquired resistance and enabling lifecycle extension of the franchise, with a first-in-human trial planned for Q4 FY26, which could generate early clinical proof-of-concept before many investors anticipate.
Despite elevated GAAP operating expenses due to nonrecurring stock-based compensation adjustments, Revolution Medicines ended Q1 FY26 with $1.9 billion in cash and investments, strengthened to $2.1 billion post-quarter from the April dual-tranche capital raise, providing a multi-year runway to execute its aggressive clinical and commercialization plans without near-term financing pressure, allowing sustained investment in global launch readiness—including recent appointments of regional GMs for APAC, Japan, and Germany—and reducing reliance on dilution or partnerships to fund pivotal trials and pre-launch activities.

▼ Bear case

Revolution Medicines faces near-term commercial execution risk as the company has not provided concrete timelines for FDA submission or approval of diraxonrasib, despite expressing urgency; the lack of specific milestones around CMC completion, clinical package readiness, or international filing strategy creates uncertainty, particularly given the complexity of launching in multiple regions sequentially, and while the expanded access program reflects strong demand, it does not guarantee rapid uptake post-approval due to reimbursement hurdles, payer skepticism toward novel oncology pricing, and the need for real-world evidence to support formulary access.
The company’s financial profile remains highly speculative, with Q1 FY26 GAAP net loss of $453.8 million and projected full-year GAAP operating expenses between $1.7 billion and $1.8 billion, driven largely by elevated R&D and G&A spending tied to clinical trial acceleration and stock-based compensation; although the $2.1 billion cash buffer provides near-term relief, the burn rate implies a cash runway of approximately 12-15 months at current loss rates, raising concerns about the need for additional financing before key data readouts from RESOLUTE-301 (NSCLC) or RESOLUTE-303 (first-line pancreatic) are available, potentially diluting shareholders if trials underperform.
Clinical development risks are underappreciated, particularly in the RESOLUTE-309 trial evaluating the zoldonrasib plus diraxonrasib doublet in second-line pancreatic cancer; while management views chemotherapy as the appropriate comparator, the unprecedented monotherapy survival benefit from diraxonrasib in RESOLUTE-302 raises the bar significantly, and demonstrating additive efficacy over an already highly active single agent may require prohibitively large effect sizes, making it difficult to show statistical and clinical superiority without enrolling impractical patient numbers, thereby risking a failed or ambiguous outcome despite biological rationale.
Safety and tolerability concerns, though downplayed, could limit real-world adoption; the peer-reviewed first-in-human trial of diraxonrasib reported treatment-related adverse events in 96% of patients, with 30% experiencing severe or life-threatening events, including rash, mucositis, nausea, and diarrhea—while deemed manageable in a trial setting, these side effects may impact quality of life and adherence in broader populations, especially elderly or comorbid patients, and could lead to dose reductions or discontinuation, potentially diminishing the observed survival benefit in real-world use compared to trial results.

Revolution Medicines faces near-term commercial execution risk as the company has not provided concrete timelines for FDA submission or approval of diraxonrasib, despite expressing urgency; the lack of specific milestones around CMC completion, clinical package readiness, or international filing strategy creates uncertainty, particularly given the complexity of launching in multiple regions sequentially, and while the expanded access program reflects strong demand, it does not guarantee rapid uptake post-approval due to reimbursement hurdles, payer skepticism toward novel oncology pricing, and the need for real-world evidence to support formulary access.
The company’s financial profile remains highly speculative, with Q1 FY26 GAAP net loss of $453.8 million and projected full-year GAAP operating expenses between $1.7 billion and $1.8 billion, driven largely by elevated R&D and G&A spending tied to clinical trial acceleration and stock-based compensation; although the $2.1 billion cash buffer provides near-term relief, the burn rate implies a cash runway of approximately 12-15 months at current loss rates, raising concerns about the need for additional financing before key data readouts from RESOLUTE-301 (NSCLC) or RESOLUTE-303 (first-line pancreatic) are available, potentially diluting shareholders if trials underperform.
Clinical development risks are underappreciated, particularly in the RESOLUTE-309 trial evaluating the zoldonrasib plus diraxonrasib doublet in second-line pancreatic cancer; while management views chemotherapy as the appropriate comparator, the unprecedented monotherapy survival benefit from diraxonrasib in RESOLUTE-302 raises the bar significantly, and demonstrating additive efficacy over an already highly active single agent may require prohibitively large effect sizes, making it difficult to show statistical and clinical superiority without enrolling impractical patient numbers, thereby risking a failed or ambiguous outcome despite biological rationale.
Safety and tolerability concerns, though downplayed, could limit real-world adoption; the peer-reviewed first-in-human trial of diraxonrasib reported treatment-related adverse events in 96% of patients, with 30% experiencing severe or life-threatening events, including rash, mucositis, nausea, and diarrhea—while deemed manageable in a trial setting, these side effects may impact quality of life and adherence in broader populations, especially elderly or comorbid patients, and could lead to dose reductions or discontinuation, potentially diminishing the observed survival benefit in real-world use compared to trial results.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2022)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2022)

Peer Comparison

Create an account

Sign In

Reset Password